Medixall (MDXL) Stock Price, News & Analysis
Company Description
Medixall (OTC Link: MDXL) is classified in the health information services industry within the Healthcare sector and carries a market capitalization of $1.2M.
MDXL has gained 43.6% over the past year. Shares last traded at $0.0056.
For FY2023, Medixall reported revenue of $309K and diluted earnings per share of -$0.04.
This page collects what Stock Titan holds for MDXL, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Medixall (MDXL) stock last closed at $0.0056. Over the past 12 months, the stock has gained 43.6%. At a market capitalization of $1.2M, MDXL is classified as a micro-cap stock with approximately 205.5M shares outstanding.
MDXL Rankings
Latest News
Medixall has 10 recent news articles. Key topics include partnership, AI, conferences. View all MDXL news →
SEC Filings
Medixall has filed 3 recent SEC filings, including 2 Form NT 10-Q, 1 Form NT 10-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all MDXL SEC filings →
Financial Highlights
Medixall generated $309K in revenue in FY2023, retaining a 23.6% gross margin. Diluted earnings per share stood at -$0.04. The company generated -$1.2M in operating cash flow. With a current ratio of 0.00, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Days to Cover History
MDXL Company Profile & Sector Positioning
Medixall (MDXL) operates in the Health Information Services industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing MDXL often look at related companies in the same sector, including Cardiocomm Solut (EKGGF), EvokAI Creative (OKAIF), Ppj Healthcare (PPJE), Newtopia (NEWUF), and Mednow (MDNWF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MDXL's relative position within its industry.